Your browser doesn't support javascript.
loading
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Bringhen, Sara; Voorhees, Peter M; Plesner, Torben; Mellqvist, Ulf-Henrik; Reeves, Brandi; Sonneveld, Pieter; Byrne, Catriona; Nordström, Eva; Harmenberg, Johan; Obermüller, Jakob; Richardson, Paul G.
Affiliation
  • Bringhen S; Division of Haematology, University of Torino, AUO Città della Salute e della Scienza di Torino, Torino, Italy.
  • Voorhees PM; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Plesner T; Department of Haematology, Vejle Hospital, Vejle and University of Southern Denmark, Vejle, Denmark.
  • Mellqvist UH; Department of Haematology, Borås Hospital, Borås, Sweden.
  • Reeves B; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Sonneveld P; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Byrne C; Oncopeptides AB, Stockholm, Sweden.
  • Nordström E; Oncopeptides AB, Stockholm, Sweden.
  • Harmenberg J; Oncopeptides AB, Stockholm, Sweden.
  • Obermüller J; Oncopeptides AB, Stockholm, Sweden.
  • Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Br J Haematol ; 193(6): 1105-1109, 2021 06.
Article in En | MEDLINE | ID: mdl-33403663
ABSTRACT
An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2021 Document type: Article Affiliation country: Italia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2021 Document type: Article Affiliation country: Italia